Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2020-12-08 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - IMU 6 pages 30.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Imugene Limited regarding a proposed issue of securities, specifically a placement or other type of issue of ordinary fully paid shares. It details the number of securities to be issued, the issue price, the consideration, and compliance with ASX listing rules. There is no financial performance data, management discussion, or audit information. The document is focused on capital raising activities and changes in the company's capital structure. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the securities issuance, not just a brief notice or report publication announcement.
2020-12-08 English
Appendix 2A and 708A Notice 17 pages 5.0MB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9 December 2020 regarding the exercise of shortfall options and the issue of shares under an underwriting agreement. It includes details about the number of options exercised, exercise price, expiration dates, and a notice under section 708A(5) of the Corporations Act 2001 about the issue of shares without disclosure under Part 6D.2 of the Act. The document is primarily an announcement of a capital raising event and share issuance, referencing Appendix 2A for further details. It does not contain financial statements, management discussion, or detailed financial results. The content aligns with updates on company fundraising and capital structure changes rather than a full financial report or regulatory certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-12-08 English
Change of Director's Interest Notice - CW 3 pages 182.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including shares and options acquired and disposed of, with dates and values. This type of document is a formal notification of personal share transactions by company directors. It is not a financial report, earnings release, or management discussion, but specifically a report of director dealings in securities. Therefore, it fits the category 'Director's Dealing' (DIRS). The document length and content confirm it is the actual notice, not just an announcement or certification.
2020-12-07 English
Appendix 3G 12 pages 452.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX, which is a notification of the issue, conversion, or payment up of equity securities. It details the issuance of unquoted securities under an employee incentive scheme, including the number and type of options issued, recipients, and other related information. This type of document is a formal announcement regarding changes in the company's capital structure, specifically the issuance of new securities. It is not a full financial report, earnings release, or management discussion, nor is it a proxy or AGM material. It fits the definition of a Share Issue/Capital Change announcement, as it informs the market about new share issues or capital changes.
2020-12-02 English
Imugene First Patient Dosed in PD1-VAXX Clinical Trial 2 pages 126.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated December 1, 2020, about dosing the first patient in a Phase I clinical trial of a new immunotherapy drug. It is a press release style announcement describing a clinical trial milestone, not a financial report or regulatory filing. There are no financial statements, no voting results, no management changes, no earnings data, no audit information, and no detailed investor presentation. The content focuses on clinical trial progress and company updates. The document length is 4636 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-11-30 English
Proposed issue of Securities - IMU 6 pages 31.1KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a placement or other type of securities issue by Imugene Limited. It includes specifics such as the number of securities to be issued, issue prices, underwriting details, and compliance with ASX listing rules. There is no financial performance data, earnings information, or management discussion. The content focuses exclusively on the announcement of a capital raising event through issuing new shares. This matches the definition of a Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing event, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2020-11-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.